Who is sponsoring NCT00745823?

NCT00745823 is sponsored by Merck Sharp & Dohme LLC.

What drugs are being tested in NCT00745823?

Interventions: Comparator: Raltegravir 400 mg b.i.d., Experimental: Raltegravir 800 mg q.d., TRUVADA™.

What is the status of NCT00745823?

NCT00745823 is currently TERMINATED.

Last reviewed 2017-02-14 · How we verify

A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Once Daily Raltegravir (MK0518) Versus Twice Daily Raltegravir, Each in Combination With TRUVADA™, in Treatment-Naïve HIV Infected Patients

NCT00745823 Phase 3 TERMINATED Results posted

A study to evaluate the safety, tolerability and efficacy of once daily Raltegravir compared to twice daily raltegravir when each is given in combination with TRUVADA™ in treatment-naïve human immunodeficiency virus (HIV)-infected patients.

Details

Lead sponsor	Merck Sharp & Dohme LLC
Phase	Phase 3
Status	TERMINATED
Enrolment	775
Start date	2008-09
Completion	2011-05

Conditions

Interventions

Comparator: Raltegravir 400 mg b.i.d.
Experimental: Raltegravir 800 mg q.d.
TRUVADA™

Primary outcomes

Number of Participants With HIV Ribonucleic Acid (RNA) <50 Copies/mL at 48 Weeks — Week 48
Number of Participants With One or More Adverse Events at 48 Weeks — Week 48
Number of Participants Who Discontinued Due to an Adverse Event at 48 Weeks — Week 48